LIVIVO - Search results -

Search results

Result 1 - 10 of total 125

Search options

Article ; Online: Ensuring Heathy Lives with the Korea Disease Control and Prevention Agency: Partnership with the Korean Diabetes Association.

Jee, Youngmee

2023 Volume 47, Issue 6, Page(s) 767–768

MeSH term(s)	Humans ; Korea ; Diabetes Mellitus/epidemiology ; Republic of Korea/epidemiology
Language	English
Publishing date	2023-11-24
Publishing country	Korea (South)
Document type	Journal Article
ZDB-ID	2602402-0
ISSN	2233-6087 ; 2233-6087
ISSN (online)	2233-6087
ISSN	2233-6087
DOI	10.4093/dmj.2023.0406
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Global Perspectives: The COVID-19 Pandemic in 2020-2021 and Beyond.

Jee, Youngmee

China CDC weekly

2021 Volume 3, Issue 7, Page(s) 142–143

Language	English
Publishing date	2021-09-14
Publishing country	China
Document type	Journal Article
ISSN	2096-7071
ISSN (online)	2096-7071
DOI	10.46234/ccdcw2021.040
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Inclusion of hepatitis C virus testing in National Health Screening to accelerate HCV elimination in South Korea.

Jee, Youngmee

Global health & medicine

2021 Volume 3, Issue 5, Page(s) 288–292

Abstract: In 2015, the World Health Organization (WHO) has set the goal of eliminating hepatitis C by reducing incidence of chronic viral hepatitis and related mortality by 2030 with the interim target of achieving 30% prevalence reduction by 2020. While The ... ...

Abstract	In 2015, the World Health Organization (WHO) has set the goal of eliminating hepatitis C by reducing incidence of chronic viral hepatitis and related mortality by 2030 with the interim target of achieving 30% prevalence reduction by 2020. While The global prevalence of hepatitis C is known to be around 1.6%, the prevalence of hepatitis C in South Korea is 0.5-0.6% based on hepatitis C virus (HCV) antibody-positive rate. Although HCV antibody test has been included in the Annual National Health and Nutrition Survey in South Korea since 2012, a national initiative to eliminate hepatitis C was initiated by small clinic-related hepatitis C outbreaks in 2015-2016. These outbreaks caused by inappropriate use of syringes in 2015-2016 prompted the revision of hepatitis C reporting and control strategies in Korea following long-term discussion on including the HCV antibody test in the National Health Screening at a certain age. Since June 3, 2017, all hepatitis C cases should be reported to the Korea Disease Control Agency (KDCA). A pilot study for early detection of hepatitis C was conducted for the 56 years old population from September 1 to October 31 in 2020 by temporarily including HCV Ab in the National Health Screening followed by HCV RNA testing for HCV antibody positive cases. The final decision to include HCV antibody test in National Health Screening will be made based on results of the pilot study in 2020. To eliminate hepatitis B & C by 2030 in South Korea, the KDCA established a comprehensive viral hepatitis control and management system in 2020 with the interim goal of achieving an antibody positive rate of 0.3% and treatment rate of 90% by 2025.
Language	English
Publishing date	2021-10-06
Publishing country	Japan
Document type	Journal Article ; Review
ISSN	2434-9194
ISSN (online)	2434-9194
DOI	10.35772/ghm.2021.01057
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: WHO International Health Regulations Emergency Committee for the COVID-19 outbreak

Youngmee Jee

Epidemiology and Health, Vol

2020 Volume 42

Abstract: To discuss whether the coronavirus disease 2019 (COVID-19) outbreak constitutes a Public Health Emergency of International Concern (PHEIC), World Health Organization (WHO) organized the 15-member International Health Regulations Emergency Committee (EC). ...

Abstract	To discuss whether the coronavirus disease 2019 (COVID-19) outbreak constitutes a Public Health Emergency of International Concern (PHEIC), World Health Organization (WHO) organized the 15-member International Health Regulations Emergency Committee (EC). On January 22-23 and January 30, 2020, EC convened and discussed whether the situation in China and other countries would constitute PHEIC and issued recommendations for WHO, China and the international community. Based on the recommendations of EC, WHO declared the COVID-19 outbreak a PHEIC. One of the purposes of the declaration of PHEIC was to alarm countries with weak public health infrastructures to prepare promptly for emerging infectious diseases (EID) and provide WHO with a framework for proactively supporting those countries. On February 3, 2020, WHO proposed the 2019 COVID-19 Strategic Preparedness and Response Plan, which includes accelerating research and development (R&D) processes as one of three major strategies. On February 11-12, 2020, WHO held the Global Research and Innovation Forum: Towards a Research Roadmap for COVID-19. The fact that a COVID-19 R&D forum was the first meeting convened after the PHEIC declaration testifies to the importance of R&D in response to EID. Korea has demonstrated a remarkable capacity in its laboratory response by conducting high-throughput COVID-19 testing and utilizing innovative drive-through samplings. These measures for early detection and screening of cases should be followed by full efforts to produce research-based evidence by thoroughly analyzing epidemiological, clinical and immunological data, which will facilitate the development of vaccines and therapeutics for COVID-19. It is expected that Korea plays a global partner for COVID-19 research by actively participating in immediate and mid/long-term priorities jointly led by WHO and global partners.
Keywords	covid-19 ; international health regulations ; emergency committee ; public health emergency of international concern ; research and development ; Medicine ; R ; covid19
Subject code	306
Language	English
Publishing date	2020-03-01T00:00:00Z
Publisher	Korean Society of Epidemiology
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: WHO International Health Regulations Emergency Committee for the COVID-19 outbreak.

Jee, Youngmee

Epidemiology and health

2020 Volume 42, Page(s) e2020013

Abstract	To discuss whether the coronavirus disease 2019 (COVID-19) outbreak constitutes a Public Health Emergency of International Concern (PHEIC), World Health Organization (WHO) organized the 15-member International Health Regulations Emergency Committee (EC). On January 22-23 and January 30, 2020, EC convened and discussed whether the situation in China and other countries would constitute PHEIC and issued recommendations for WHO, China and the international community. Based on the recommendations of EC, WHO declared the COVID-19 outbreak a PHEIC. One of the purposes of the declaration of PHEIC was to alarm countries with weak public health infrastructures to prepare promptly for emerging infectious diseases (EID) and provide WHO with a framework for proactively supporting those countries. On February 3, 2020, WHO proposed the 2019 COVID-19 Strategic Preparedness and Response Plan, which includes accelerating research and development (R&D) processes as one of three major strategies. On February 11-12, 2020, WHO held the Global Research and Innovation Forum: Towards a Research Roadmap for COVID-19. The fact that a COVID-19 R&D forum was the first meeting convened after the PHEIC declaration testifies to the importance of R&D in response to EID. Korea has demonstrated a remarkable capacity in its laboratory response by conducting high-throughput COVID-19 testing and utilizing innovative drive-through samplings. These measures for early detection and screening of cases should be followed by full efforts to produce research-based evidence by thoroughly analyzing epidemiological, clinical and immunological data, which will facilitate the development of vaccines and therapeutics for COVID-19. It is expected that Korea plays a global partner for COVID-19 research by actively participating in immediate and mid/long-term priorities jointly led by WHO and global partners.
MeSH term(s)	Betacoronavirus ; COVID-19 ; Civil Defense ; Coronavirus ; Coronavirus Infections/epidemiology ; Disease Outbreaks/prevention & control ; Global Health ; Humans ; International Health Regulations ; Pandemics ; Pneumonia, Viral/epidemiology ; Public Health ; Public Health Practice ; SARS-CoV-2 ; World Health Organization
Keywords	covid19
Language	English
Publishing date	2020-03-19
Publishing country	Korea (South)
Document type	Journal Article ; Review
ZDB-ID	2590698-7
ISSN	2092-7193 ; 2092-7193
ISSN (online)	2092-7193
ISSN	2092-7193
DOI	10.4178/epih.e2020013
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: WHO International Health Regulations Emergency Committee for the COVID-19 outbreak

Jee, Youngmee

Epidemiol Health

Abstract	To discuss whether the coronavirus disease 2019 (COVID-19) outbreak constitutes a Public Health Emergency of International Concern (PHEIC), World Health Organization (WHO) organized the 15-member International Health Regulations Emergency Committee (EC). On January 22-23 and January 30, 2020, EC convened and discussed whether the situation in China and other countries would constitute PHEIC and issued recommendations for WHO, China and the international community. Based on the recommendations of EC, WHO declared the COVID-19 outbreak a PHEIC. One of the purposes of the declaration of PHEIC was to alarm countries with weak public health infrastructures to prepare promptly for emerging infectious diseases (EID) and provide WHO with a framework for proactively supporting those countries. On February 3, 2020, WHO proposed the 2019 COVID-19 Strategic Preparedness and Response Plan, which includes accelerating research and development (R&D) processes as one of three major strategies. On February 11-12, 2020, WHO held the Global Research and Innovation Forum: Towards a Research Roadmap for COVID-19. The fact that a COVID-19 R&D forum was the first meeting convened after the PHEIC declaration testifies to the importance of R&D in response to EID. Korea has demonstrated a remarkable capacity in its laboratory response by conducting high-throughput COVID-19 testing and utilizing innovative drive-through samplings. These measures for early detection and screening of cases should be followed by full efforts to produce research-based evidence by thoroughly analyzing epidemiological, clinical and immunological data, which will facilitate the development of vaccines and therapeutics for COVID-19. It is expected that Korea plays a global partner for COVID-19 research by actively participating in immediate and mid/long-term priorities jointly led by WHO and global partners.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #32192278
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Comparison of Waning Neutralizing Antibody Responses Against the Omicron Variant 6 Months After Natural SARS-CoV-2 Infection (With/Without subsequent COVID-19 Vaccination) Versus 2-dose COVID-19 Vaccination.

Lim, So Yun / Park, Soonju / Kim, Ji Yeun / Kim, Seungtaek / Jee, Youngmee / Kim, Sung-Han

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

2022

Abstract: Following SARS-CoV-2 infection, subsequent ChAdOx1 nCoV-19 induced similar neutralizing antibody levels against the original strain but significantly higher levels against the Omicron variant compared to those who were not vaccinated. Prior SARS-CoV-2 ... ...

Abstract	Following SARS-CoV-2 infection, subsequent ChAdOx1 nCoV-19 induced similar neutralizing antibody levels against the original strain but significantly higher levels against the Omicron variant compared to those who were not vaccinated. Prior SARS-CoV-2 infection exhibited higher neutralization antibody titers than vaccination alone for both original strains and the Omicron variant.
Language	English
Publishing date	2022-06-10
Publishing country	United States
Document type	Journal Article
ZDB-ID	1099781-7
ISSN	1537-6591 ; 1058-4838
ISSN (online)	1537-6591
ISSN	1058-4838
DOI	10.1093/cid/ciac435
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1505: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 480: Show issues

Order via subito

Details ▾

Article ; Online: Effect of multiple comorbidities on mortality in chronic obstructive pulmonary disease among Korean population: a nationwide cohort study.

Kim, Youngmee / Kim, Ye-Jee / Cho, Won-Kyung

BMC pulmonary medicine

2021 Volume 21, Issue 1, Page(s) 56

Abstract: Background: The effects of comorbidities on chronic obstructive pulmonary disease (COPD) have been usually studied individually in the past. In this study, we aimed to investigate the comorbidities associated with mortality, the effect of multimorbidity ...

Abstract	Background: The effects of comorbidities on chronic obstructive pulmonary disease (COPD) have been usually studied individually in the past. In this study, we aimed to investigate the comorbidities associated with mortality, the effect of multimorbidity on mortality and other factors associated with mortality among Korean COPD population. Methods: The Korean National Health Insurance Service-National Sample Cohort version 2.0, collected between 2002 and 2015, was used. Among COPD patients [entire cohort (EC), N = 12,779], 44% of the participants underwent additional health examination, and they were analysed separately [health-screening cohort (HSC), N = 5624]. Fifteen comorbidities previously reported as risk factors for mortality were studied using Cox proportional hazards regression models. Results: Total mortality rates were 38.6 per 1000 person-years (95% CI 37.32-40.01) and 27.4 per 1000 person-years (95% CI 25.68-29.22) in EC and HSC, respectively. The most common causes of death were disease progression, lung cancer, and pneumonia. Only some of the comorbidities had a direct impact on mortality. Multimorbidity, assessed by the number of comorbid diseases, was an independent risk factor of all-cause mortality in both cohorts and was a risk factor of respiratory mortality only in HSC. The Kaplan-Meier analysis showed significant differences in survival trajectories according to the number of comorbidities in all-cause mortality but not in respiratory mortality. Low BMI, old age and male sex were independent risk factors for both mortalities in both cohorts. Conclusions: The number of comorbidities might be an independent risk factor of COPD mortality. Multimorbidity contributes to all-cause mortality in COPD, but the effect of multimorbidity is less evident on respiratory mortality.
MeSH term(s)	Aged ; Asthma/epidemiology ; Bronchiectasis/epidemiology ; Cardiovascular Diseases/epidemiology ; Cause of Death ; Cohort Studies ; Comorbidity ; Diabetes Mellitus/epidemiology ; Digestive System Neoplasms/epidemiology ; Disease Progression ; Dyslipidemias/epidemiology ; Female ; Gastroesophageal Reflux/epidemiology ; Humans ; Kaplan-Meier Estimate ; Liver Diseases/epidemiology ; Lung Neoplasms/epidemiology ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Mortality ; Multimorbidity ; Osteoporosis/epidemiology ; Pneumonia/mortality ; Proportional Hazards Models ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Pulmonary Disease, Chronic Obstructive/mortality ; Renal Insufficiency, Chronic/epidemiology ; Republic of Korea/epidemiology ; Risk Factors ; Thyroid Neoplasms/epidemiology
Language	English
Publishing date	2021-02-11
Publishing country	England
Document type	Journal Article
ZDB-ID	2059871-3
ISSN	1471-2466 ; 1471-2466
ISSN (online)	1471-2466
ISSN	1471-2466
DOI	10.1186/s12890-021-01424-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Effect of the interval between birth and second dose of hepatitis B vaccine on perinatal transmission of hepatitis B virus.

Yang, Tae Un / Vargas-Zambrano, Juan C / Park, Hang A / Jung, Chae Won / Kim, Dongwook / Jee, Youngmee

Human vaccines & immunotherapeutics

2023 Volume 19, Issue 3, Page(s) 2278940

Abstract: Preventing perinatal transmission is important for hepatitis B (HepB) elimination. We conducted a retrospective cohort study to assess the interval between HepB birth-dose (HepB-BD) to second-dose (HepB-SD) vaccination on perinatal transmission. Among 39, ...

Abstract	Preventing perinatal transmission is important for hepatitis B (HepB) elimination. We conducted a retrospective cohort study to assess the interval between HepB birth-dose (HepB-BD) to second-dose (HepB-SD) vaccination on perinatal transmission. Among 39,313 infants born to HepB s-antigen (HBsAg)-positive mothers from a Korean national database 38,411 (97.7%) had completed timely immunophylaxis with HepB-BD 41,572 (99.8%) with hepatitis B immune globulin, and 1027 (2.6%) were HBsAg-positive at ≥ 9 months. Maternal factors (i.e. HepB e-antigen status, age, or nationality) were associated with an increased risk of infection whereas short gestational length decreased it. The HepB-BD - HepB-SD interval (<8 vs. ≥8 weeks) did not alter the risk.
MeSH term(s)	Infant ; Pregnancy ; Female ; Humans ; Hepatitis B Vaccines ; Hepatitis B Surface Antigens ; Hepatitis B virus ; Infectious Disease Transmission, Vertical/prevention & control ; Retrospective Studies ; Hepatitis B/prevention & control
Chemical Substances	Hepatitis B Vaccines ; Hepatitis B Surface Antigens ; gamma-hydroxy-gamma-ethyl-gamma-phenylbutyramide (67880-30-2)
Language	English
Publishing date	2023-11-13
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2664176-8
ISSN	2164-554X ; 2164-5515
ISSN (online)	2164-554X
ISSN	2164-5515
DOI	10.1080/21645515.2023.2278940
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6967: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Japanese encephalitis in the Western Pacific Region: Implication from the Republic of Korea.

Choe, Young June / Jee, Youngmee / Takashima, Yoshihiro / Lee, Jong-Koo

Vaccine

2020 Volume 38, Issue 13, Page(s) 2760–2763

Abstract: Japanese encephalitis (JE) is endemic in the Western Pacific Region. We aim to describe the regional status of control of JE, based on the World Health Organization (WHO) surveillance data, and to share the experience from the Republic of Korea. ... ...

Abstract	Japanese encephalitis (JE) is endemic in the Western Pacific Region. We aim to describe the regional status of control of JE, based on the World Health Organization (WHO) surveillance data, and to share the experience from the Republic of Korea. Substantial progress has been made in the region to date; however, epidemiologic changes have not been delineated. The vaccination coverage should be addressed to close the immunity gap. The lessons learned from Korea may aid in establishing a high-quality surveillance system with a sustainable JE vaccination program in order to prepare for new challenges that this region will face.
MeSH term(s)	Encephalitis Virus, Japanese ; Encephalitis, Japanese/epidemiology ; Encephalitis, Japanese/prevention & control ; Epidemiological Monitoring ; Humans ; Japanese Encephalitis Vaccines ; Republic of Korea/epidemiology ; World Health Organization
Chemical Substances	Japanese Encephalitis Vaccines
Language	English
Publishing date	2020-02-25
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	605674-x
ISSN	1873-2518 ; 0264-410X
ISSN (online)	1873-2518
ISSN	0264-410X
DOI	10.1016/j.vaccine.2020.02.061
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1930: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 458: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito